SLC5A2 and type 2 diabetes mellitus: Sixty-two percent of physicians (134/197 endocrinologists and 113/203 PCPs) reported they prescribe SGLT2 inhibitors in type 2 diabetes mellitus patients at low risk of diabetic kidney disease.